tradingkey.logo

Codexis Inc

CDXS
View Detailed Chart

2.450USD

-0.040-1.61%
Close 09/19, 16:00ETQuotes delayed by 15 min
221.12MMarket Cap
LossP/E TTM

Codexis Inc

2.450

-0.040-1.61%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.61%

5 Days

+0.82%

1 Month

-14.63%

6 Months

-7.89%

Year to Date

-48.64%

1 Year

-23.68%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
108 / 506
Overall Ranking
211 / 4720
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
7.083
Target Price
+184.47%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Growing
The company is in a growing phase, with the latest annual income totaling USD 59.34M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 94.32.
Fairly Valued
The company’s latest PE is -3.04, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 75.27M shares, decreasing 8.29% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.59M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.67.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Ticker SymbolCDXS
CompanyCodexis Inc
CEODr. Stephen G. Dilly, Ph.D.
Websitehttps://www.codexis.com/
KeyAI